What is William Blair’s Forecast for APLS Q4 Earnings?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Analysts at William Blair issued their Q4 2025 earnings estimates for Apellis Pharmaceuticals in a research report issued on Monday, October 28th. William Blair analyst L. Hanbury-Brown anticipates that the company will post earnings of $0.23 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.37) per share.

A number of other equities research analysts have also weighed in on APLS. The Goldman Sachs Group raised their price objective on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Royal Bank of Canada initiated coverage on shares of Apellis Pharmaceuticals in a research report on Friday, October 25th. They set a “sector perform” rating and a $25.00 price target for the company. UBS Group cut their price target on shares of Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Wells Fargo & Company reduced their price objective on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Tuesday, September 24th. Finally, Robert W. Baird dropped their target price on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a research report on Monday, September 23rd. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $65.41.

Apellis Pharmaceuticals Stock Down 1.6 %

Shares of Apellis Pharmaceuticals stock opened at $27.26 on Wednesday. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18. Apellis Pharmaceuticals has a 1-year low of $26.28 and a 1-year high of $73.80. The business has a 50-day moving average of $32.52 and a 200-day moving average of $37.94. The company has a market capitalization of $3.31 billion, a PE ratio of -7.88 and a beta of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The firm had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The firm’s revenue was up 110.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.02) EPS.

Institutional Trading of Apellis Pharmaceuticals

Large investors have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. grew its position in Apellis Pharmaceuticals by 14.4% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 14,068 shares of the company’s stock worth $827,000 after purchasing an additional 1,766 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Apellis Pharmaceuticals by 254.5% in the 1st quarter. Principal Financial Group Inc. now owns 84,604 shares of the company’s stock worth $4,973,000 after buying an additional 60,741 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Apellis Pharmaceuticals in the 1st quarter valued at approximately $3,218,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Apellis Pharmaceuticals during the 1st quarter valued at $89,000. Finally, Oppenheimer Asset Management Inc. boosted its position in Apellis Pharmaceuticals by 8.3% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 8,694 shares of the company’s stock worth $511,000 after acquiring an additional 664 shares during the period. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insider Activity

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the sale, the director now owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).